Analyst picks & changes

Interneuron Pharmaceuticals Inc.

(IPIC)

Patricia Lea of Vector Securities International initiated coverage with a "buy." She said the stock is likely to rise suddenly this year when the FDA announces that its Endocrine

Read the full 331 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE